The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Key findings of the pooled analysis of the TOURMALINE-MM3 and MM4 trials
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the results from a pooled analysis of the TOURMALINE-MM3 (NCT02181413) and TOURMALINE-MM4 (NCT02312258) studies, which are investigating measurable residual disease (MRD) dynamics during maintenance therapy with ixazomib versus placebo in transplant-eligible and ineligible myeloma patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
